TARGETING NEW CANCER SOLUTIONS
No patient should be denied the cancer care they need simply because some options are in short supply or unavailable. Yet, all too often, this is what happens.
At the core of many oncology therapies are radioisotopes. However, increasingly limited supply inhibits patient outcomes and the development of new therapies.
Innovation
Advancements with radioisotopes
Nusano is combining time-proven technology from universities and world-class research centers with our own breakthrough, patented particle acceleration technology. The result is the first significant advancement in medical radioisotope production in decades – a platform fitting the needs of today and designed for cancer-fighting radiopharmaceuticals of tomorrow.
Inspiration
Life Saving Benefits
Health care has used radioisotopes for decades. But, if supply does not keep up with demand, patients will lose out on the benefits of these lifesaving, proven tools.
Implications
a healthy tomorrow
Nusano’s patented technologies and methods are poised to transform radioisotope production and usher in an exciting new era in cancer care. When it opens, our state-of-the-art facility in West Valley City, Utah will produce radioisotopes quickly, efficiently, and affordably. This will make desperately needed resources available to hospitals and cancer clinics around the world and offer those with life-threatening diseases hope for a healthier tomorrow.
Nusano
Leadership
Nusano is driven by an experienced team of scientists, engineers, and innovators, and guided by leaders with deep expertise in health care, business development and operations.
Chris Lowe
Chief Executive Officer
Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. Read more >>
HOWARD C. LEWIN, MD, FACC, FASNC
CO-FOUNDER & CHIEF PRODUCT DEVELOPMENT OFFICER
Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine. Read more >>
GLENN B. ROSENTHAL, PH.D.
CO-FOUNDER & CHIEF TECHNOLOGY OFFICER
Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer.
Read more >>
Pushkar Bedekar
Chief Financial Officer
A 20-year veteran of the pharmaceuticals industry, Bedekar served as the CFO of U.S. Oncology for Novartis prior to joining Nusano. He oversees the company’s financial operations, including accounting, financial planning, tax, and treasury functions.
Kevin Haehl
Chief Product Officer
A 35-year veteran of pharma and biotech, Haehl drives value-creating opportunities for Nusano customers by ensuring excellence throughout the company’s product and supply chain operations.
Chris Ignace
SVP, Scientific Affairs
Ignace spent 13 years at Cardinal Health Nuclear and Precision Solutions in a variety of leadership roles. At Nusano, he applies his deep understanding of radiopharmaceutical development and regulatory processes to drive improved alignment and outcomes for the company and its customers.
Rohan Jain
Chief Commercial Officer
Jain served as VP & Head of Novartis’ U.S. Radioligand Therapy Product Portfolio prior to joining Nusano. His Commercial team works with customers and prospects to enable current and future cancer therapeutics development.
Maggie Kruse
VP, People & Culture
Kruse is a HR executive whose career spans life sciences, financial services, technology, and manufacturing. She is growing Nusano’s innovative, science-driven culture to support current and future radioisotope applications.
Jzaneen Lalani
Chief Business Officer
Lalani has over 20 years’ experience managing life sciences companies across a wide variety of functional areas, including as a general counsel of public and privately-held companies. She oversees Nusano’s HR, legal, government affairs, and special projects functions.
Nusano
Board of Directors
Scott Holbrook
NUSANO BOARD CHAIR & GM-CSO, Pharmalogic
Scott has over twenty years’ experience in the field of molecular imaging and therapeutics.
DELL LOY HANSEN
FOUNDER & CEO, WASATCH GROUP
Dell Loy Hansen is the Founder and Chief Executive Officer of the Wasatch Group and is responsible for the overall management of its enterprises and affiliates.
John dahlstrom
EVP - General Counsel, Wasatch Property Management
John is General Counsel of Wasatch Property Management, a fully integrated real estate development, construction, property management and guaranty capital company operating in six states.
Aaron Gerszewski
Managing Director, Wasatch Equity Partners
Aaron is managing partner at Wasatch Equity Partners, an investment firm with more than $4 billion assets under management.
Andy Harrison
CEO, Section 32
Andy is Managing Director and CEO of Section 32, a venture capital fund investing at the frontiers of technology.
Michael Pellini
Managing Partner, Section 32
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology.
additional directors
company managers
Chris Lowe (CEO) and Howard Lewin (CPDO), also serve on the Board of Directors.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates